A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Inclusion Criteria:
Have a body mass index (BMI) ≥35.0 kilogram/square meter (kg/m²).
Have established cardiovascular (CV) disease with at least 1 of the following:
Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion Criteria:
Springfield, Illinois 62711, United States
Buenos Aires, Buenos Aires C1426ABP, Argentina
CABA, Buenos Aires C1060ABN, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires 1056, Argentina
Ciudad de Buenos Aires, Buenos Aires C1012AAR, Argentina
Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
Capital, Córdoba Province X5008HHW, Argentina
Godoy Cruz, Mendoza Province 5501, Argentina
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
North York, Ontario M6B 3H7, Canada
Chihuahua City, Chihuahua 31110, Mexico
Mexico City, Mexico City 11650, Mexico
San Luis Potosí City, San Luis Potosí 78200, Mexico
Krakow, Lesser Poland Voivodeship 31-261, Poland
Lodz, Łódź Voivodeship 90338, Poland
Ferrol, A Coruña [La Coruña] 15405, Spain